NCT06577077View on ClinicalTrials.gov

Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Rhinitis, Allergic, Perennial
Interventions
DRUG

Product CM9241GRU

01 tablet in the morning and 01 tablet in the evening for 14 days

DRUG

Placebo

01 tablet in the morning and 01 tablet in the evening for 14 days

Sponsors
All Listed Sponsors
lead

Ache Laboratorios Farmaceuticos S.A.

INDUSTRY